113 related articles for article (PubMed ID: 38762210)
1. Berberine directly targets AKR1B10 protein to modulate lipid and glucose metabolism disorders in NAFLD.
Yang S; Cao SJ; Li CY; Zhang Q; Zhang BL; Qiu F; Kang N
J Ethnopharmacol; 2024 Oct; 332():118354. PubMed ID: 38762210
[TBL] [Abstract][Full Text] [Related]
2. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.
Xu X; Zhu XP; Bai JY; Xia P; Li Y; Lu Y; Li XY; Gao X
FASEB J; 2019 Jun; 33(6):7289-7300. PubMed ID: 30848932
[TBL] [Abstract][Full Text] [Related]
3. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
4. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
5. Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways.
You L; Wang T; Li W; Zhang J; Zheng C; Zheng Y; Li S; Shang Z; Lin J; Wang F; Qian Y; Zhou Z; Kong X; Gao Y; Sun X
J Ethnopharmacol; 2024 Jul; 329():118165. PubMed ID: 38588984
[TBL] [Abstract][Full Text] [Related]
6. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
Zhang J; Du H; Shen M; Zhao Z; Ye X
J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhetinic acid attenuates disturbed vitamin a metabolism in non-alcoholic fatty liver disease through AKR1B10.
Shi L; Guo S; Zhang S; Gao X; Liu A; Wang Q; Zhang T; Zhang Y; Wen A
Eur J Pharmacol; 2020 Sep; 883():173167. PubMed ID: 32485245
[TBL] [Abstract][Full Text] [Related]
8. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
[TBL] [Abstract][Full Text] [Related]
9. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.
Zhang YP; Deng YJ; Tang KR; Chen RS; Liang S; Liang YJ; Han L; Jin L; Liang ZE; Chen YN; Yang QH
Curr Med Sci; 2019 Feb; 39(1):37-43. PubMed ID: 30868489
[TBL] [Abstract][Full Text] [Related]
10. Berberine protects mice against type 2 diabetes by promoting PPARγ-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis.
Chen Y; Li Q; Zhao S; Sun L; Yin Z; Wang X; Li X; Iwakiri Y; Han J; Duan Y
Biochem Pharmacol; 2023 Dec; 218():115928. PubMed ID: 37979703
[TBL] [Abstract][Full Text] [Related]
11. Berberrubine, a Main Metabolite of Berberine, Alleviates Non-Alcoholic Fatty Liver Disease
Yang S; Cao S; Li C; Zhang J; Liu C; Qiu F; Kang N
Front Pharmacol; 2022; 13():913378. PubMed ID: 35873595
[TBL] [Abstract][Full Text] [Related]
12. Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways.
Wang Y; Tai YL; Zhao D; Zhang Y; Yan J; Kakiyama G; Wang X; Gurley EC; Liu J; Liu J; Liu J; Lai G; Hylemon PB; Pandak WM; Chen W; Zhou H
Cells; 2021 Jan; 10(2):. PubMed ID: 33494295
[TBL] [Abstract][Full Text] [Related]
13. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles.
Yuan X; Wang J; Tang X; Li Y; Xia P; Gao X
J Transl Med; 2015 Jan; 13():24. PubMed ID: 25623289
[TBL] [Abstract][Full Text] [Related]
14. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
15. Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4α miR122 Pathway.
Wei S; Zhang M; Yu Y; Lan X; Yao F; Yan X; Chen L; Hatch GM
PLoS One; 2016; 11(3):e0152097. PubMed ID: 27011261
[TBL] [Abstract][Full Text] [Related]
16. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
[TBL] [Abstract][Full Text] [Related]
17. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
Hong Y; Choi SI; Hong E; Kim GH
J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
[TBL] [Abstract][Full Text] [Related]
18. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver.
Yu M; Alimujiang M; Hu L; Liu F; Bao Y; Yin J
Int J Biol Sci; 2021; 17(7):1693-1707. PubMed ID: 33994854
[TBL] [Abstract][Full Text] [Related]
19. Biochanin A improves hepatic steatosis and insulin resistance by regulating the hepatic lipid and glucose metabolic pathways in diet-induced obese mice.
Park HS; Hur HJ; Kim SH; Park SJ; Hong MJ; Sung MJ; Kwon DY; Kim MS
Mol Nutr Food Res; 2016 Sep; 60(9):1944-55. PubMed ID: 27145114
[TBL] [Abstract][Full Text] [Related]
20. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
